Nanoform Finland Plc., an innovative nanoparticle medicine-enabling company, today announced that it has launched its sparse-data AI solution (STARMAP^® Online) as a secure online portal for direct use by its current and future partners.

Since its inception in 2020, STARMAP^® has been actively used by Nanoform to provide its clients with a confident assessment of their molecules’ suitability for Controlled Expansion of Supercritical Solutions (CESS^®)¹ nanoparticle engineering.

STARMAP^® is a digital version of the CESS^® technology that enables in silico experiments to determine which molecules should be nanoformed.

Nanoform’s legacy processes involved handling all analyses in-house after receiving specific molecule attributes from its clients.

STARMAP^® Online has been launched as a direct request from Nanoform’s current and future partners who seek to maintain the level of confidence STARMAP^® offers, while integrating it into their own in-house molecule-selection processes.  STARMAP^® Online creates the opportunity for clients to perform large numbers of in-silico CESS^® experiments from their desktop, prior to approaching Nanoform to perform experimental validation.  This approach further supports Nanoform’s green ambition by ensuring that Nanoform progresses the molecules with the greatest probability of success.

STARMAP^® Online offers increased user confidence through:

• Security and safety – the interface has been developed in alignment with ISO27001:2017 standards.
• Client submissions are seen only by clients (not by Nanoform), allowing molecules to be screened without sharing structures. Outputs are presented directly to the client via the system.
• Scalability and agility: The ability to manage thousands of molecules in a single submission to support the selection of candidates from molecule libraries is possible.
• Novel insights: STARMAP^® Online holds a database of over 17,000 pre-analyzed, public-domain disclosed drugs and candidates. Clients can request thematic evaluations and understand the power of CESS^® in different therapeutic areas, target classes, and disease areas.

“This May the 4^th, STARMAP^® Online opens up new galaxies of potential and we are excited to increase access for the pharma community. The technology has a significant potential impact, allowing viable CESS^® candidates to be rapidly identified. STARMAP^® Online has the potential to transform the lives of patients by accelerating the development of new therapies, supporting our mission to touch the lives of a billion patients with nanoformed medicines,” said Prof. Edward Hæggström, Chief Executive Officer of Nanoform.

¹ (CESS^® is a nanoparticle platform technology that produces pure homogeneous drug particles from solution in an excipient-free process. By reducing the particle size e.g., from 10 microns to 50 nm, the specific surface area can be increased by as much as 1000-fold, thereby improving dissolution rate, solubility, and bioavailability. Consequently, Nanoform can help pharma partners progress molecules into development that otherwise may not have been possible. It also opens up exciting possibilities for a wide range of novel drug delivery applications.)

For further information, please contact:

Christian Jones, CCO

Christian.jones@nanoform.com / +44 7804 474771

For investor relations queries, please contact:

Henri von Haartman, Director of Investor Relations

hvh@nanoform.com / +46 7686 650 11

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to improve the lives of patients by overcoming drug development and delivery challenges through the use of Nanoform’s game-changing technologies. Enhanced by the most talented minds in physics, AI, biology and engineering, Nanoform’s capabilities include GMP manufacturing and its nanoparticle engineering and formulation services span the small to large molecule development space. By solving key issues in drug solubility and bioavailability, Nanoform works to drive forward market success, enable novel drug delivery applications and unlock the power of “small.” Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806. For more information please visit http://www.nanoform.com